IQVIA: The Market May Be Missing The AI & Data Story

IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion.